This broccoli lowers a blood marker linked to heart disease, but it hasn’t been shown to prevent heart attacks or strokes.
Scientific Claim
Consumption of high glucoraphanin broccoli does not reduce heart disease events, as the study only measured LDL cholesterol as a biomarker, not clinical outcomes.
Original Statement
“The paper overstates the mechanism by suggesting the Nrf2/PTEN/AMPK pathway is the cause — this is a hypothesis based on animal studies, not proven in humans. Also, claims that 'broccoli reduces heart disease risk' are unsupported — LDL-C reduction is a biomarker, not a clinical outcome.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The study design (biomarker-only outcome) cannot assess clinical events. The claim correctly reflects this limitation and aligns with the study’s own cautionary note.
Evidence from Studies
Supporting (0)
Contradicting (1)
Diet rich in high glucoraphanin broccoli reduces plasma LDL cholesterol: Evidence from randomised controlled trials
This study found that eating a special kind of broccoli lowers 'bad' cholesterol, which is a major cause of heart disease — so saying it doesn’t help heart health is wrong, even if they didn’t count heart attacks.